Scientific Expertise

Dec 1-3

RT-qPCR and Sequencing Testing Supporting SARS-CoV-2 Vaccine Clinical Trials

Presented By Mark Wissel

This informative webinar; featuring Karina Eterovic, PhD, R&D Director of Oncology Diagnostics at Eurofins Viracor, entitled: Exploring the application of comprehensive genomic profiling in oncology therapy development.

Sept 28 - Oct 1

qPCR/sequencing assay development to support vaccine clinical studies and trials

Presented by Mark Wissel

Jul 29

This informative webinar, featuring our flow cytometry expert, Dr. Brian Maybruck, will focus on the use of Flow Cytometry for rare cell quantitation, and its application in drug development.

Flow cytometry is a very powerful and reliable alternative to many other methods used for clinical drug development. Consider that it can simultaneously measure multiple parameters on tens of thousands of cells, with a resolution down to a single cell level, robustly and rapidly (greater than 1000 samples per day).

Check out the latest BioPharma Services newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.

Check out the latest BioPharma Services newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.

Click here to check out the Bioanalysis ZONE podcast on T-cell immunity monitoring and assay development, featuring Steven Kleiboeker, PhD, our VP of Research & Development at Eurofins Viracor BioPharma.

A global pharmaceutical company partnered with Eurofins Viracor BioPharma to conduct immunogenicity testing for a new vaccine candidate. Eurofins Viracor BioPharma provided specialized expertise and developed precise, robust, and sensitive assays to support the sponsor's clinical trial needs.

Emerging immunotherapies like cancer vaccines and oncolytic viruses show promise for treating cancer. Oncolytic virus therapies face challenges with virus neutralization and clearance. This case study explores methods to characterize the biodistribution and transmissibility of an oncolytic virus candidate in a clinical trial.